KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Net Margin: 2009-2025

Historic Net Margin for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to 9.55%.

  • Teva Pharmaceutical Industries' Net Margin rose 2599.00% to 9.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.77%, marking a year-over-year increase of 2735.00%. This contributed to the annual value of -11.89% for FY2024, which is 408.00% down from last year.
  • Teva Pharmaceutical Industries' Net Margin amounted to 9.55% in Q3 2025, which was up 45.60% from 6.56% recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Net Margin ranged from a high of 9.55% in Q3 2025 and a low of -54.79% during Q4 2022.
  • For the 3-year period, Teva Pharmaceutical Industries' Net Margin averaged around -14.17%, with its median value being -13.14% (2023).
  • The largest annual percentage gain for Teva Pharmaceutical Industries' Net Margin in the last 5 years was 9,188bps (2021), contrasted with its biggest fall of 3,061bps (2021).
  • Teva Pharmaceutical Industries' Net Margin (Quarterly) stood at -27.24% in 2021, then plummeted by 2,754bps to -54.79% in 2022, then spiked by 58bps to -54.21% in 2023, then skyrocketed by 4,754bps to -6.67% in 2024, then spiked by 2,599bps to 9.55% in 2025.
  • Its Net Margin was 9.55% in Q3 2025, compared to 6.56% in Q2 2025 and 5.47% in Q1 2025.